162 related articles for article (PubMed ID: 37244355)
21. DNA repair gene polymorphisms, tumor control, and treatment toxicity in prostate cancer patients treated with permanent implant prostate brachytherapy.
Carignan D; Lessard T; Villeneuve L; Desjardins S; Magnan S; Després P; Martin AG; Foster W; Guillemette C; Lévesque É; Vigneault E
Prostate; 2020 May; 80(8):632-639. PubMed ID: 32201973
[TBL] [Abstract][Full Text] [Related]
22. Single-nucleotide polymorphisms studied for associations with urinary toxicity from (125)I prostate brachytherapy implants.
Usmani N; Leong N; Martell K; Lan L; Ghosh S; Pervez N; Pedersen J; Yee D; Murtha A; Amanie J; Sloboda R; Murray D; Parliament M
Brachytherapy; 2014; 13(3):285-91. PubMed ID: 24656733
[TBL] [Abstract][Full Text] [Related]
23. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer.
Burri RJ; Stock RG; Cesaretti JA; Atencio DP; Peters S; Peters CA; Fan G; Stone NN; Ostrer H; Rosenstein BS
Radiat Res; 2008 Jul; 170(1):49-59. PubMed ID: 18582155
[TBL] [Abstract][Full Text] [Related]
24. Comparison of statistical machine learning models for rectal protocol compliance in prostate external beam radiation therapy.
Jones S; Hargrave C; Deegan T; Holt T; Mengersen K
Med Phys; 2020 Apr; 47(4):1452-1459. PubMed ID: 31981427
[TBL] [Abstract][Full Text] [Related]
25. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.
Zapatero A; Roch M; Büchser D; Castro P; Fernández-Banda L; Pozo G; Liñán O; Martin de Vidales C; Cruz-Conde A; García-Vicente F
Clin Transl Oncol; 2017 Sep; 19(9):1161-1167. PubMed ID: 28374321
[TBL] [Abstract][Full Text] [Related]
26. Use of a Novel Nonparametric Version of DEPTH to Identify Genomic Regions Associated with Prostate Cancer Risk.
MacInnis RJ; Schmidt DF; Makalic E; Severi G; FitzGerald LM; Reumann M; Kapuscinski MK; Kowalczyk A; Zhou Z; Goudey B; Qian G; Bui QM; Park DJ; Freeman A; Southey MC; Al Olama AA; Kote-Jarai Z; Eeles RA; Hopper JL; Giles GG;
Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1619-1624. PubMed ID: 27539266
[TBL] [Abstract][Full Text] [Related]
27. Genetic sequence variants are associated with severity of lower urinary tract symptoms and prostate cancer susceptibility.
Helfand BT; Hu Q; Loeb S; McVary KT; Catalona WJ
J Urol; 2013 Mar; 189(3):845-8. PubMed ID: 23159463
[TBL] [Abstract][Full Text] [Related]
28. Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis.
Orozco G; Goh CL; Al Olama AA; Benlloch-Garcia S; Govindasami K; Guy M; Muir KR; Giles GG; Severi G; Neal DE; Hamdy FC; Donovan JL; Kote-Jarai Z; Easton DF; Eyre S; Eeles RA
BJU Int; 2013 Jun; 111(7):1148-55. PubMed ID: 22985493
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide association study of prostate cancer mortality.
Penney KL; Pyne S; Schumacher FR; Sinnott JA; Mucci LA; Kraft PL; Ma J; Oh WK; Kurth T; Kantoff PW; Giovannucci EL; Stampfer MJ; Hunter DJ; Freedman ML
Cancer Epidemiol Biomarkers Prev; 2010 Nov; 19(11):2869-76. PubMed ID: 20978177
[TBL] [Abstract][Full Text] [Related]
30. Rectal and Urethro-Vesical Subregions for Toxicity Prediction After Prostate Cancer Radiation Therapy: Validation of Voxel-Based Models in an Independent Population.
Mylona E; Ebert M; Kennedy A; Joseph D; Denham J; Steigler A; Supiot S; Acosta O; de Crevoisier R
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1189-1195. PubMed ID: 32673785
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive Analysis of Multiple Cohort Datasets Deciphers the Utility of Germline Single-Nucleotide Polymorphisms in Prostate Cancer Diagnosis.
Zhang W; Dong Y; Sartor O; Zhang K
Cancer Prev Res (Phila); 2021 Jul; 14(7):741-752. PubMed ID: 33866309
[TBL] [Abstract][Full Text] [Related]
32. Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy.
Thurner EM; Krenn-Pilko S; Langsenlehner U; Renner W; Gerger A; Kapp KS; Langsenlehner T
Strahlenther Onkol; 2014 Mar; 190(3):304-9. PubMed ID: 24424626
[TBL] [Abstract][Full Text] [Related]
33. GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis.
Margalit DN; Jordahl KM; Werner L; Wang X; Gwo-Shu Lee M; Penney KL; Batista JL; Martin NE; Chan JM; Kantoff PW; Stampfer MJ; Nguyen PL; Mucci LA
Clin Genitourin Cancer; 2015 Aug; 13(4):370-377.e1. PubMed ID: 25662905
[TBL] [Abstract][Full Text] [Related]
34. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study.
Barnett GC; Coles CE; Elliott RM; Baynes C; Luccarini C; Conroy D; Wilkinson JS; Tyrer J; Misra V; Platte R; Gulliford SL; Sydes MR; Hall E; Bentzen SM; Dearnaley DP; Burnet NG; Pharoah PD; Dunning AM; West CM
Lancet Oncol; 2012 Jan; 13(1):65-77. PubMed ID: 22169268
[TBL] [Abstract][Full Text] [Related]
35. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer.
Damaraju S; Murray D; Dufour J; Carandang D; Myrehaug S; Fallone G; Field C; Greiner R; Hanson J; Cass CE; Parliament M
Clin Cancer Res; 2006 Apr; 12(8):2545-54. PubMed ID: 16638864
[TBL] [Abstract][Full Text] [Related]
36. Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-/very high-risk prostate cancer: A dosimetric analysis of toxicity.
Sakurai T; Takamatsu S; Shibata S; Iwata K; Taka M; Gabata T; Kumano T; Makino T; Mizokami A
Jpn J Radiol; 2020 Dec; 38(12):1197-1208. PubMed ID: 32737768
[TBL] [Abstract][Full Text] [Related]
37. Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride.
Dai JY; LeBlanc M; Goodman PJ; Lucia MS; Thompson IM; Tangen CM
Cancer Prev Res (Phila); 2019 Feb; 12(2):113-120. PubMed ID: 30538099
[TBL] [Abstract][Full Text] [Related]
38. No Association Between Polygenic Risk Scores for Cancer and Development of Radiation Therapy Toxicity.
Barnett GC; Kerns SL; Dorling L; Fachal L; Aguado-Barrera ME; Martínez-Calvo L; Jandu HK; Welsh C; Tyrer J; Coles CE; Haviland JS; Parker C; Gómez-Caamaño A; Calvo-Crespo P; Sosa-Fajardo P; Burnet NG; Summersgill H; Webb A; De Ruysscher D; Seibold P; Chang-Claude J; Talbot CJ; Rattay T; Parliament M; De Ruyck K; Rosenstein BS; Pharoah PDP; Dunning AM; Vega A; West CML;
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(3):494-501. PubMed ID: 35840111
[TBL] [Abstract][Full Text] [Related]
39. Association between metformin medication, genetic variation and prostate cancer risk.
Lee MJ; Jayalath VH; Xu W; Lu L; Freedland SJ; Fleshner NE; Kulkarni GS; Finelli A; van der Kwast TH; Hamilton RJ
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):96-105. PubMed ID: 32424261
[TBL] [Abstract][Full Text] [Related]
40. Association of genetic variants in autophagy-lysosome pathway genes with susceptibility and survival to prostate cancer.
Zhu Q; Meng Y; Li S; Xin J; Du M; Wang M; Cheng G
Gene; 2022 Jan; 808():145953. PubMed ID: 34500048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
